Celcuity (CELC) EBITDA (2016 - 2026)
Celcuity's (CELC) quarterly EBITDA came in at -$49.2 million in Q4 2025, down 35.06% YoY from -$75.8 million in Q4 2024, and down 14.82% on a QoQ basis from -$42.8 million in Q3 2025.
Celcuity (CELC) EBITDA (2016 - 2026) Analysis & Trends
Celcuity (CELC) has 10 years of EBITDA data on file, last reported at -$49.2 million in Q4 2025.
- Quarterly EBITDA fell 35.06% year-over-year to -$49.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$172.2 million (down 52.02% YoY) and the FY2025 annual result came in at -$172.2 million, down 52.02% from the prior year.
- EBITDA eased to -$49.2 million in Q4 2025, from -$42.8 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$2.8 million in Q1 2021 to a low of -$49.2 million in Q4 2025.
- A 5-year average of -$21.0 million and a median of -$17.0 million in 2023 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2021 — EBITDA sank 516.25% — and 2022, when it advanced 29.63%.
- Tracing CELC's EBITDA over 5 years: stood at -$6.3 million in 2021, then tumbled by 84.14% to -$11.6 million in 2022, then plunged by 69.51% to -$19.7 million in 2023, then plunged by 84.65% to -$36.4 million in 2024, then plunged by 35.06% to -$49.2 million in 2025.
- The last three EBITDA figures came in at -$49.2 million (Q4 2025), -$42.8 million (Q3 2025), and -$44.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Celcuity | 4.50 Bn | 4.50 Bn | - | -66.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -66.12 Mn |
| Dec 31, 2025 | -49.20 Mn |
| Sep 30, 2025 | -42.85 Mn |
| Jun 30, 2025 | -44.01 Mn |
| Mar 31, 2025 | -36.13 Mn |
| Dec 31, 2024 | -36.43 Mn |
| Sep 30, 2024 | -30.06 Mn |
| Jun 30, 2024 | -24.28 Mn |
| Mar 31, 2024 | -22.49 Mn |
| Dec 31, 2023 | -19.73 Mn |
| Sep 30, 2023 | -18.90 Mn |
| Jun 30, 2023 | -15.06 Mn |
| Mar 31, 2023 | -12.55 Mn |
| Dec 31, 2022 | -11.64 Mn |
| Sep 30, 2022 | -10.64 Mn |
| Jun 30, 2022 | -9.60 Mn |
| Mar 31, 2022 | -7.51 Mn |
| Dec 31, 2021 | -6.32 Mn |
| Sep 30, 2021 | -5.60 Mn |
| Jun 30, 2021 | -13.64 Mn |